Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.
Press releases published on June 12, 2025
Sharecare introduces new interactive solutions to elevate health literacy and increase condition-specific treatment adherence
GlobeNewswire
·
June 12, 2025
ATLANTA, June 12, 2025 (GLOBE NEWSWIRE) -- Sharecare, the health tech company that helps to improve care quality, drive better outcomes, and lower costs across the healthcare ecosystem, today announced the first two of 10 new innovative solutions designed …
Fortrea Adopts Limited-Duration Stockholder Rights Plan
GlobeNewswire
·
June 12, 2025
DURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that its Board of Directors (the “Board”) has unanimously adopted a limited-duration stockholder …
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative
GlobeNewswire
·
June 12, 2025
GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
GlobeNewswire
·
June 12, 2025
PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE: LH), a global leader of …
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
GlobeNewswire
·
June 12, 2025
Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: …
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
GlobeNewswire
·
June 12, 2025
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered …
SteraMist Named Disinfection and Decontamination Products Company of the Year 2025
GlobeNewswire
·
June 12, 2025
FREDERICK, Md., June 12, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today is proud to announce it has been honored with the prestigious …
Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon
GlobeNewswire
·
June 12, 2025
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics) Raises full year revenue outlook to $80 - $100 million (excluding ACT Genomics) IM8 contributed $5.7 million in Q1, with $2.8 million in March alone …
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
GlobeNewswire
·
June 12, 2025
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical …
Werewolf Therapeutics to Participate in the BIO International Convention
GlobeNewswire
·
June 12, 2025
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate …
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
GlobeNewswire
·
June 12, 2025
Key complex product approval in the Affordable Medicines segment this year Commercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the …
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
GlobeNewswire
·
June 12, 2025
OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading …
Nectero Medical Secures Category III CPT Codes for Investigational Therapy to Treat Small- to Medium-Sized AAAs
GlobeNewswire
·
June 12, 2025
TEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero Medical, a clinical-stage biotechnology company developing therapies for aneurysmal disease, announced today that the American Medical Association’s CPT Editorial Panel has approved two Category III CPT …
DiagnaMed Appoints John Karagiannidis as President & CEO; Fabio Chianelli Transitions to Director Role Strengthening Strategic Partnership with QIMC to Accelerate Natural Hydrogen Development in Ontario
GlobeNewswire
·
June 12, 2025
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("”DiagnaMed” or “DMED") (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extraction technologies, today announced the appointment of John …
Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
GlobeNewswire
·
June 12, 2025
WOBURN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, …
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
GlobeNewswire
·
June 12, 2025
Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the third …
Aayush Wellness Bridging Ancient Ayurvedic Wisdom with Modern Wellness offering Aayush Herbal Masala – A Natural Alternative
GlobeNewswire
·
June 12, 2025
NEW DELHI, India, June 12, 2025 (GLOBE NEWSWIRE) -- Aayush Wellness Limited, a trailblazer in India's preventive healthcare sector, seamlessly integrates the time-honored principles of Ayurveda with contemporary scientific advancements. Their product line …
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
GlobeNewswire
·
June 12, 2025
Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study …
Angitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2115, A Bispecific Antibody for the Treatment of Osteogenesis Imperfecta
GlobeNewswire
·
June 12, 2025
WESTLAKE VILLAGE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced topline …
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
GlobeNewswire
·
June 12, 2025
Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of …